Posted by Michael Wonder on 01 Oct 2025
Imfinzi’s bid for coverage faces Keytruda’s double-edged impact in Korea
30 September 2025 - AstraZeneca's immuno-oncology drug Imfinzi (durvalumab) is attempting to expand its reimbursement coverage, but its competitor, MSD's Keytruda (pembrolizumab), is acting as a complex variable.
In other words, Keytruda has become a double-edged sword for its rival drug: pressuring Imfinzi’s price downward while simultaneously creating a short-term opportunity in bile duct cancer.
